Autocrine human growth hormone expression leads to resistance of MCF-7 cells to tamoxifen

Medical Oncology

Volumn 27, Issue 2, 2010, Pages 474-480

  Mojarrad, Majid ^a   Momeny, Majid ^b   Mansuri, Fatemeh ^a   Abdolazimi, Yassan ^a   Tabrizi, Mina Hajifaraj ^a   Ghaffari, Seyed Hamidollah ^b   Tavangar, Seyed Mohammad ^b   Modarressi, Mohammad Hussein ^a,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Autocrine; Drug resistance; GPR30; Growth hormone

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; COMPLEMENTARY DNA; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; G PROTEIN COUPLED RECEPTOR 30; HUMAN GROWTH HORMONE; MESSENGER RNA; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SU 6665; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; AUTOCRINE EFFECT; BREAST ADENOCARCINOMA; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; HORMONE ACTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STABLE TRANSFECTION; TREATMENT RESPONSE;

ADENOCARCINOMA; AUTOCRINE COMMUNICATION; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN GROWTH HORMONE; HUMANS; TAMOXIFEN;

EID: 77956916084     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9237-5     Document Type: Article

References (53)

1. Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol. 2000;18:3172-3186.
2. Katzenellenbogen BS, Montano MM, Ediger TR, Sun J, Ekena K, Lazennec G. Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Prog Horm Res. 2000;55:163-93.
3. Early Breast Cancer Trialist' Collaborative Group (EBCTC). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687-17. doi:10.1016/S0140-6736(05)66544-0. (Pubitemid 40719106)
4. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell Cycle. 1998;95:927-37.
5. Funakoshi T, Yanai A, Shinoda K, Kawano MM, Mizukami Y. G protein-coupled receptor 30 is an estrogen receptor in the plasma membrane. Biochem Biophys Res Commun. 2006;346(3):904-10. doi:10.1016/j.bbrc.2006.05.191.
6. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Ando S, et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol. 2006; 20(3):631-46. doi:10.1210/me.2005-0280. (Pubitemid 43291214)
7. Vivacqua A, Bonofiglio D, Albanito L, Madeo A, Rago V, Carpino A, et al. 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30. Mol Pharmacol. 2006;70 (4):1414-23. doi:10.1124/mol.106.026344. (Pubitemid 44435994)
8. Prossnitz ER, Sklar LA, Oprea TI, Arterburn JB. GPR30: a novel therapeutic target in estrogen-related disease. Trends Pharmacol Sci. 2008;29(3):116-23.
9. Matsuda K, Sakamoto H, Mori H, Hosokawa K, Kawamura A, Itose M, et al. Expression and intracellular distribution of the G protein-coupled receptor 30 in rat hippocampal formation. Neurosci Lett. 2008;441(1):94-9. doi:10.1016/j.neulet.2008.05.108.
10. Wang C, Prossnitz ER, Roy SK. G protein-coupled receptor 30 expression is required for estrogen stimulation of primordial follicle formation in the hamster ovary. Endocrinology. 2008;149 (9):4452-61. doi:10.1210/en.2008-0441.
11. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 2005;307(5715):1625-30. doi: 10.1126/science.1106943. (Pubitemid 40354745)
12. Kleuser B, Malek D, Gust R, Pertz HH, Potteck H. 17-Betaestradiol inhibits transforming growth factor-beta signaling and function in breast cancer cells via activation of extracellular signal-regulated kinase through the G protein-coupled receptor 30. Mol Pharmacol. 2008;74(6):1533-43. doi:10.1124/mol.108.046854.
13. Sternlicht M. Key stages in mammary gland development: the cues that regulate ductal branching morphogenesis. Breast Cancer Res. 2006;8(1):201. doi:10.1186/bcr1368.
14. Kleinberg D. Early mammary development: growth hormone and IGF-1. J Mammary Gland Biol Neoplasia. 1997;2(1):49-57. doi: 10.1023/A:1026373513521.
15. Luft R, Olivecrona H, Sjogren B. Hypophysectomy in man. Nord Med. 1952;47(11):351-4.
16. Ray BS, Pearson OH. Hypophysectomy in treatment of disseminated breast cancer. Surg Clin North Am. 1962;42:419-33.
17. Divisova J, Kuiatse I, Lazard Z, Weiss H, Vreeland F, Hadsell DL, et al. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat. 2006;98(3): 315-27. doi:10.1007/s10549-006-9168-1. (Pubitemid 44195602)
18. Mukhina S, Mertani HC, Guo K, Lee KO, Gluckman PD, Lobie PE. Phenotypic conversion of human mammary carcinoma cells by autocrine human growth hormone. Proc Natl Acad Sci USA. 2004;101(42):15166-71. doi:10.1073/pnas.0405881101. (Pubitemid 39391736)
19. Mertani HC, Garcia-Caballero T, Lambert A, Gérard F, Palayer C, Boutin JM, Vonderhaar BK, Waters MJ, Lobie PE, Morel G. Cellular expression of growth hormone and prolactin receptors in human breast disorders. Int J Cancer. 1998;79(2):202-11. doi: 10.1002/(SICI)1097-0215(19980417)79:2\202::AID-IJC17[3. 0.CO;2-B.
20. Antony GJ, Van Wyk JJ, French FS, Weaver RP, Dugger GS, Timmons RL, et al. Influence of pituitary stalk section on growth hormone, insulin and TSH secretion in women with metastatc breast cancer. J Clin Endocrinol Metab. 1969;29(9):1238-50.
21. Emerman JT, Leahy M, Gout PW, Bruchovsky N. Elevated growth hormone levels in sera from breast cancer patients. Horm Metab Res. 1985;17(8):421-4. doi:10.1055/s-2007-1013563.
22. Slootweg MC, de Groot RP, Herrmann-Erlee MP, Koornneef I, Kruijer W, Kramer YM. Growth hormone induces expression of c-jun and jun B oncogenes and employs a protein kinase C signal transduction pathway for the induction of c-fos oncogene expression. J Mol Endocrinol. 1991;6(2):179-88. doi:10.1677/jme.0.0060179.
23. Stoll BA. Growth hormone and breast cancer. Clin Oncol (R Coll Radiol). 1992;4(1):4-5. doi:10.1016/S0936-6555(05)80761-7.
24. Waters MJ, Conway-Campbell BL. The oncogenic potential of autocrine human growth hormone in breast cancer. Proc Natl Acad Sci USA. 2004;101(42):14992-3. doi:10.1073/pnas.0406396101. (Pubitemid 39391704)
25. Wagner K, Hemminki K, Israelsson E, Grzybowska E, Klaes R, Chen B, et al. Association of polymorphisms and haplotypes in the human growth hormone 1 (GH1) gene with breast cancer. Endocr Relat Cancer. 2005;12(4):917-28. doi:10.1677/erc.1.01073. (Pubitemid 41815785)
26. Raccurt M, Lobie PE, Moudilou E, Garcia-Caballero T, Frappart L, Morel G, Mertani HC. High stromal and epithelial human gh gene expression is associated with proliferative disorders of the mammary gland. J Endocrinol. 2002;175: 307-18. doi:10.1677/joe.0.1750307. (Pubitemid 35414378)
27. Zhu T, Starling-Emerald B, Zhang X, Lee KO, Gluckman PD, Mertani HC, Lobie PE. Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone. Cancer Res. 2005;65(1):317-24.
28. Perry JK, Emerald BS, Mertani HC, Lobie PE. The oncogenic potential of growth hormone. Growth Horm IGF Res. 2006;16: 277-89. doi:10.1016/j.ghir.2006. 09.006. (Pubitemid 44793716)
29. Perry JK, Mohankumar KM, Emerald BS, Mertani HC, Lobie PE. The contribution of growth hormone to mammary neoplasia. J Mammary Gland Biol Neoplasia. 2008;13:131-45. doi:10.1007/s10911-008-9070-z.
30. Filardo EJ, Quinn JA, Frackelton AR Jr, Bland KI. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol. 2002;16(1):70-84. doi:10.1210/me.16.1.70. (Pubitemid 34044499)
31. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, et al. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem. 2004;279(26):27008-16. doi: 10.1074/jbc.M403588200. (Pubitemid 38812536)
32. Filardo EJ, Thomas P. GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol Metab. 2005;16(8):362-7. doi:10.1016/j.tem.2005.08.005. (Pubitemid 41338741)
33. Hsieh YC, Yu HP, Frink M, Suzuki T, Choudhry MA, Schwacha MG, et al. G protein-coupled receptor 30-dependent protein kinase A pathway is critical in nongenomic effects of estrogen in attenuating liver injury after trauma-hemorrhage. Am J Pathol. 2007;170(4):1210-8. doi:10.2353/ajpath.2007. 060883. (Pubitemid 47339329)
34. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, et al. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res. 2007;67(4):1859-66. doi:10.1158/0008-5472.CAN-06-2909. (Pubitemid 46383413)
35. Ahmad AM, Hopkins MT, Thomas J, Ibrahim H, Fraser WD, Vora JP. Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement. Clin Endocrinol (Oxf). 2001;54(6):709-17. doi: 10.1046/j.1365-2265.2001.01275.x. (Pubitemid 34208881)
36. Marino M, Galluzzo P, Ascenzi P. Estrogen signaling multiple pathways to impact gene transcription. Curr Genomics. 2006;7(8): 497-508. doi:10.2174/138920206779315737. (Pubitemid 46068961)
37. Kaganowicz A, Farkouh NH, Frantz AG, Blaustein AU. Ectopic human growth hormone in ovaries and breast cancer. J Clin Endocrinol Metab. 1979;48(1):5-8.
38. Kaulsay KK, Mertani HC, Törnell J, Morel G, Lee KO, Lobie PE. Autocrine stimulation of human mammary carcinoma cell proliferation by human growth hormone. Exp Cell Res. 1999;250: 35-50. doi:10.1006/excr.1999.4492. (Pubitemid 29391569)
39. Prossnitz ER, Arterburn JB, Sklar LA. GPR30: a G proteincoupled receptor for estrogen. Mol Cell Endocrinol. 2007;265-266:138-42. doi:10.1016/j.mce.2006. 12.010. (Pubitemid 46273957)
40. Filardo EJ. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol. 2002;80(2):231-8. doi:10.1016/S0960-0760(01)00190-X. (Pubitemid 34233742)
41. Filardo EJ, Quinn JA, Sabo E. Association of the membrane estrogen receptor, GPR30, with breast tumor metastasis and transactivation of the epidermal growth factor receptor. Steroids. 2008;73(9-10):870-3. doi:10.1016/j.steroids.2007.12.025.
42. Revankar CM, Mitchell HD, Field AS, Burai R, Corona C, Ramesh C, et al. Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30. ACS Chem Biol. 2007;2(8): 536-44. doi:10.1021/cb700072n. (Pubitemid 350011324)
43. Prossnitz ER, Oprea TI, Sklar LA, Arterburn JB. The ins and outs of GPR30: a transmembrane estrogen receptor. J Steroid Biochem Mol Biol. 2008;109(3-5):350-3. doi:10.1016/j.jsbmb.2008.03.006.
44. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr. Estrogeninduced activation of Erk-1 and Erk-2 requires the G proteincoupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HBEGF. Mol Endocrinol. 2000;14(10):1649-60. doi:10.1210/me.14.10.1649.
45. Albanito L, Sisci D, Aquila S, Brunelli E, Vivacqua A, Madeo A, et al. Epidermal growth factor inducesGprotein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology. 2008;149(8):3799-808. doi:10.1210/en.2008-0117.
46. Zhang Z, Duan L, Du X, Ma H, Park I, Lee C, et al. The proliferative effect of estradiol on human prostate stromal cells is mediated through activation of ERK. Prostate. 2008;68(5):508-16. doi:10.1002/pros.20722. (Pubitemid 351500211)
47. Kanda N, Watanabe S. 17beta-estradiol stimulates the growth of human keratinocytes by inducing cyclin D2 expression. J Invest Dermatol. 2004;123(2):319-28. doi:10.1111/j.0022-202X.2004.12645.x. (Pubitemid 38951827)
48. Kamanga-Sollo E, White ME, Chung KY, Johnson BJ, Dayton WR. Potential role of G-protein-coupled receptor 30 (GPR30) in estradiol-17beta-stimulated IGF-I mRNA expression in bovine satellite cell cultures. Domest Anim Endocrinol. 2008;35(3):254-62. doi:10.1016/j.domaniend.2008.06.001.
49. Sirianni R, Chimento A, Ruggiero C, De Luca A, Lappano R, Ando S, et al. The novel estrogen receptor, G protein-coupled receptor 30, mediates the proliferative effects induced by 17betaestradiol on mouse spermatogonial GC-1 cell line. Endocrinology. 2008;149(10):5043-51. doi:10.1210/en.2007-1593.
50. Prakash Pandey D, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D. Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J. 2009;28:523-32.
51. Zujewski J. Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention. Environ Mol Mutagen. 2002;39:264-70.
52. Roy RN, Gerulath AH, Cecutti A, Bhavani BR. Effect of tamoxifen treatment on the endometrial expression of human insulin-like growth factors and their receptor mRNAs. Mol Cell Endocrinol. 2000;165:173-8. doi:10.1016/S0303-7207(00) 00248-3. (Pubitemid 30625195)
53. Lobie PE, García-Aragón J,Wang BS, Baumbach WR,Waters MJ. Cellular localization of the growth hormone receptor/binding proteins in the male and female reproductive systems. Endocrinology. 1990;126:2214-21.